PFIZER Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Pfizer has an attractive 7.2% dividend yield, but this healthcare giant might be a riskier dividend stock than you want to own....

Scott Gottlieb, former FDA commissioner and current board member of Pfizer and Illumina, joins CNBC's 'Squawk on the Street' to discuss expectations for a CDC panel's review of vaccines this week, what's most at stake, and much more....

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock....

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Saisei Ventures, a leading investment firm focused on advancing Japanese biotechnology and therapeutic innovations, today announced that Mr. James Feliciano has been appointed venture partner. With more than 20 years of experience as a pharmaceutical executive in Japan, Mr. Feliciano is a world-class leader in advancing innovative therapies and guiding global teams to success. Most recently, he founded 3C Advisors GK, a Tokyo-based strategic advisory firm partnering with organizations to navigate the complexities of the Japanese market and drive impactful results. Prior to 3C Advisors, Mr. Feliciano served as president and general manager of Japan operations at AbbVie, where he oversaw strategic initiatives across multiple therapeutic areas, driving strategic planning and operational performance. He also held the role of president of Japan operations at Merck KGaA, where he led large-scale organizational strategy and execution. Earlier in his career at Pfizer, Mr. Felici...

How does $700 in annual income sound for every $10,000 in shares owned?...

Ein Bericht über mögliche Todesfälle von Kindern im Zusammenhang mit Corona-Impfungen hat an der Wall Street einen Kurssturz ausgelöst. BioNTech, Moderna, Pfizer und Novavax verloren deutlich an Wert.. --- Die US-Regierung untersucht demnach, ob 25 Todesfälle von Kindern im Zusammenhang mit Corona-Impfstoffen stehen könnten. Grundlage sind Einträge im Vaccine Adverse Event Reporting System (VAERS), einem bundesweiten Meldesystem für Nebenwirkungen.. --- Die US-Gesundheitsbehörden werten nun die gemeldeten Fälle aus. Dabei werden Autopsieberichte geprüft, Gespräche mit Angehörigen geführt und medizinische Akten analysiert. Erst wenn diese Daten ausgewertet sind, könne über einen möglichen kausalen Zusammenhang entschieden werden..

Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths. read more...

Frankfurt (www.aktiencheck.de) - Pfizer-Aktienanalyse von XTB: Die Experten von XTB nehmen die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) in einer aktuellen Marktanalyse unter die Lupe. Laut einem Bericht der Washington Post plane die Trump-Administration, COVID-19-Impfstoffe mit dem Tod von 25 Kindern in Verbindung zu bringen. [mehr]...

Vax Stocks Tumble As Trump Admin To Link COVID Shots To Child Deaths Shares in vaccine stocks were sharply lower on Friday after a report that the Trump administration is set to announce the deaths of 25 children linked to COVID-19 vaccines, according to the Washington Post. The findings are based on VAERS, a federal database that tracks vaccine injuries operated by the CDC.  Trump health officials plan to include the pediatric deaths claim in a presentation next week to an influential panel of advisers to the CDC that is considering new coronavirus vaccine recommendations, which affect access to the shots and whether they're free. As a result shares in Pfizer, BionNTech, and Moderna spiked sharply lower in Friday trade: Developing... Tyler Durden Fri, 09/12/2025 - 11:56...

The report says officials plan to include the claim in a presentation next week to a key vaccine panel that advises the CDC on shot access and coverage....

Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant....

Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

EZB belässt Zinsen stabil. Die Fed dürfte kommende Woche trotz hartnäckiger Inflation wegen dem schwachen Arbeitsmarkt die Zinsen senken. Klarna mit starkem IPO, Sotheby's leidet am Kunstmarkt. Novo Nordisk streicht Jobs. Pfizer und Prismo Metals zeigen Turnaround-Ambitionen....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

In the most recent trading session, Pfizer (PFE) closed at $24.83, indicating a +1.04% shift from the previous trading day....

BridgeBio Pharma Inc. is challenging Pfizer Inc. and Alnylam Pharmaceuticals, Inc. with a heart medicine that it says has better results at a lower cost. But it claims rivals are using questionable tactics to compete in the multibillion-dollar market....

Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus....

Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvalsCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a research and development leader at Catabasis, Pfizer, Sanofi and Gilead. Dr. Fahrner has been involved with the development of more than 17 approved medicines, including Vpriv and Elaprase, which were granted accelerated approvals by the U.S. Food and Drug Administration (USFDA). Dr. Fahrner received his PhD in Biochemistry and Molecular Biology from UCLA. Dr. Agajanov brings nearly 30 years of experience in clinical operatio...